FibroGen Gelecekteki Büyüme

Future kriter kontrolleri 0/6

FibroGen şirketinin gelirinin yıllık 1.4% oranında düşmesi, yıllık kazançlarının ise yıllık 71.4% oranında artması bekleniyor. EPS'nin yıllık 74.5% oranında büyümesi bekleniyor.

Anahtar bilgiler

71.4%

Kazanç büyüme oranı

74.5%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.3%
Gelir büyüme oranı	-1.4%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	13 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding

Oct 29

The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%

Aug 19

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding

Jul 04

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Mar 22

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

Feb 05

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Dec 22

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Nov 24

Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Apr 18

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Feb 13

The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Nov 12

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Oct 09

FibroGen completes patient enrollment for Roxadustat to treat anemia in patients

Aug 26

FibroGen Q2 2022 Earnings Preview

Aug 05

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Jul 06

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Mar 31

Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook

Mar 05

Is FibroGen (NASDAQ:FGEN) Using Debt In A Risky Way?

Dec 08

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:FGEN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	177	-9	N/A	N/A	2
12/31/2025	152	-44	N/A	N/A	2
12/31/2024	173	-89	N/A	N/A	2
9/30/2024	180	-122	-126	-126	N/A
6/30/2024	174	-168	-203	-202	N/A
3/31/2024	167	-240	-275	-273	N/A
12/31/2023	148	-284	-318	-315	N/A
9/30/2023	155	-294	-352	-349	N/A
6/30/2023	131	-322	-319	-317	N/A
3/31/2023	116	-307	-242	-239	N/A
12/31/2022	141	-294	-185	-146	N/A
9/30/2022	123	-362	-188	-148	N/A
6/30/2022	263	-220	-118	-52	N/A
3/31/2022	258	-281	-112	-46	N/A
12/31/2021	235	-290	-112	-82	N/A
9/30/2021	284	-215	-66	-34	N/A
6/30/2021	172	-231	-85	-80	N/A
3/31/2021	190	-183	92	96	N/A
12/31/2020	176	-189	78	82	N/A
9/30/2020	119	-229	40	44	N/A
6/30/2020	108	-311	13	18	N/A
3/31/2020	257	-110	-166	-161	N/A
12/31/2019	257	-77	-84	-79	N/A
9/30/2019	357	42	-58	-51	N/A
6/30/2019	353	49	-22	-15	N/A
3/31/2019	205	-90	-28	-22	N/A
12/31/2018	213	-86	-84	-76	N/A
9/30/2018	136	-141	-68	-60	N/A
6/30/2018	147	-123	N/A	-87	N/A
3/31/2018	133	-132	N/A	-71	N/A
12/31/2017	131	-121	N/A	-67	N/A
9/30/2017	132	-121	N/A	-84	N/A
6/30/2017	122	-121	N/A	-67	N/A
3/31/2017	181	-64	N/A	-3	N/A
12/31/2016	183	-58	N/A	7	N/A
9/30/2016	172	-79	N/A	-14	N/A
6/30/2016	162	-100	N/A	-50	N/A
3/31/2016	193	-67	N/A	6	N/A
12/31/2015	181	-86	N/A	-19	N/A
9/30/2015	172	-85	N/A	-3	N/A
6/30/2015	167	-79	N/A	4	N/A
3/31/2015	136	-98	N/A	-4	N/A
12/31/2014	138	-60	N/A	22	N/A
9/30/2014	134	-24	N/A	24	N/A
6/30/2014	191	43	N/A	128	N/A
3/31/2014	117	-5	N/A	30	N/A
12/31/2013	102	-15	N/A	26	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: FGEN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: FGEN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: FGEN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: FGEN şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi bekleniyor (yılda -1.4% ).

Yüksek Büyüme Geliri: FGEN şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -1.4% ).

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: FGEN 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

FibroGen Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus estimates of losses per share improve by 17%

Price target decreased by 17% to US$10.38

Consensus revenue estimates decrease by 13%, EPS upgraded

Price target decreased by 25% to US$19.00

Consensus EPS estimates fall by 20%, revenue upgraded

Price target increased by 16% to US$24.83

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding

FibroGen Receives Nasdaq Notification of Non-Compliance with Minimum Bid Price Requirement

The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies

Consensus estimates of losses per share improve by 17%

FibroGen, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding

FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell 3000 Index

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

FibroGen, Inc. Announces FDA Clearance of Investigational New Drug Application for FG-3165, A Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at the 2024 American Society of Clinical Oncology Annual Meeting

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet

FibroGen, Inc. to Report Q1, 2024 Results on May 06, 2024

FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting

Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals Announce Settlement with FibroGen, Inc

Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

CEO & Director recently bought US$95k worth of stock

FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer

Full year 2023 earnings: EPS and revenues miss analyst expectations

FibroGen, Inc. to Report Q4, 2023 Results on Feb 26, 2024

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

New major risk - Financial position

FibroGen, Inc. Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Now 25% undervalued after recent price drop

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Now 30% undervalued after recent price drop

New minor risk - Financial position

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target decreased by 17% to US$10.38

FibroGen, Inc. Appoints Thane Wettig as Chief Executive Officer

Mark Eisner Resigns as Chief Medical Officer of Fibrogen, Inc., Effective September 8, 2023

Insufficient new directors

Fibrogen, Inc. Announces Topline Results from Lelantos-2, A Phase 3 Clinical Study of Pamrevlumab in Ambulatory Muscular Dystrophy

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Fibrogen, Inc. Announces Chief Executive Officer Changes

FibroGen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Consensus revenue estimates decrease by 13%, EPS upgraded

Price target decreased by 25% to US$19.00

Now 81% undervalued after recent price drop

Insider notifies of intention to sell stock

FibroGen, Inc. Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

FibroGen, Inc. Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Consensus EPS estimates fall by 20%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Insider recently sold US$124k worth of stock

CEO & Director recently sold US$1.2m worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 16% to US$24.83

FibroGen, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Price target increased by 21% to US$21.33

Price target increased to US$17.60

Chief Financial Officer notifies of intention to sell stock

Now 20% undervalued

Price target increased to US$16.40

The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Price target increased to US$16.40